共查询到20条相似文献,搜索用时 62 毫秒
1.
马晓迪 《国外畜牧学(猪与禽)》2018,(1)
广东旺大集团股份有限公司(以下简称"旺大集团"),作为中国饲料工业协会理事单位、中国农业健康产业联盟副秘书长单位、广东省饲料行业协会副会长单位、广州市饲料行业协会会长单位、广州市农业龙头企业协会秘书长单位,旗下拥有预混料企业7家、配合料企业2家、销售贸易公司1家、核心料企业1家,并全部100%持股。旺大集团长期专业、专注于"绿色安全、优质高效"猪用清洁生物饲料,生产和销售猪用预混料、浓缩料、全价料,凭借快速增长、免疫增强、植物保健等核心独特技术,打造公司"产品力、服务力、品牌力"。第一代产品以"速增长、拉骨架"著称,确立了肉猪预混料领导品牌的地位;第二代产品以高免疫、好过渡的特点获得养殖户广泛认可;第三代产品凭借营养免疫、效益高的特点横空出世,并多次荣膺中国名优产品、广东省无抗饲料技术创新企业、广东省著名商标、广东省高新技术企业、广东省品牌产品、广东省重点农业龙头企业等殊荣。笔者有幸跟随CPICP取经团参观旺大集团(图1),并采访了集团董事长钟世强先生(图2)。以下是采访内容。 相似文献
2.
3.
4.
5.
6.
《中国畜牧业》2018,(21)
正1.1999年12月28日,广东旺大饲料新技术有限公司正式成立。2.2000年1月1日,旺大第一批产品投入市场。3.2001年10月,被中国质量检测协会评定为"国家权威检测质量达标放心品牌"。4.2002年6月,成为"广东省养猪行业协会会员"。5.2002年10月,成为"广州市饲料工业协会第三届理事单位"。6.2002年12月,国家出入境检验检疫局颁发"出口饲料生产企业备案证"。7.2003年1月,中国质量万里行评为"产品质量服务质量无投诉用户满意品牌"。8.2003年7月,中国质量认证中心认可广州首家通过"ISO9001∶2000国际质量管理体系认证"预混料企业。 相似文献
7.
8.
9.
旺大集团是一家依托国内外生物工程高新技术、专业化、规模化研发、生产、销售猪预混料、浓缩料的高科技企业集团。十年来,旺大坚决采用“品牌传播与服务营销相结合”的战略,推出了“技术推广会、疾病诊治、养殖全员培训、生猪买卖、原料检测、兽医药房、VCD及资料、旺大养猪协会、种猪测定、经营管理、猪场设计”等11项服务,实现对顾客的感性需求,完成对顾客的理性承诺。 相似文献
10.
11.
12.
13.
14.
廉江市蚕种场始建于1980年,二十几年来经历了蚕种市场的几起几落,1981年投产至2003年共生产蚕种106.02万张,年产蚕种最高是2001年的11.7万张,最低的是1988年的0.8万张,历年平均年产约4.6万张。我场有职工33人,1988年人均年产蚕种仅约0.14万张, 相似文献
15.
16.
17.
The highest DNA concentration so far recorded from organs of turkey chicken one day after hatching was the lung value of 8.61 +/- 0.20 mg/g of fresh matter, while the lowest level amounted to 1.92 +/- 0.11 mg/g and was linked to the myocardium. DNA concentrations in the spleen went up from 5.93 +/- 0.26 mg/g on the first day to 13.04 +/- 0.93 mg/g on the 224th day. The highest total amount of DNA on the 224th day was 314.6 +/- 30.23 mg/g in the liver. A high RNA concentration on the first day from hatching was 8.74 +/- 0.14 mg/g in the liver and the lowest 2.51 +/- 0.12 mg/g in the myocardium. DNA levels for the whole period under review (first through 224th days) rose by the following factors: 246.3 in the spleen, 87.4 in the pancreas, 76.6 in the liver, 60 in the duodenum, 40.5 in the kidneys, 18 in the lung, and 31.3 in the myocardium. Functional implications relating to DNA, RNA, and protein variations are discussed in some detail. 相似文献
18.
19.
In order to continue to produce livestock in a sustainable fashion, it is suggested that what was used in the past will continue to form the mainstay of future control. For the foreseeable future, we must conserve what we have, and use it in combination with all the principles of integrated pest management, namely strategic and focussed treatments of animals, environmental control of breeding sites, disease management (including the principles of enzootic stability), and resistant breeds. Whilst new technologies, such as the development of vaccines both against the insect pest in some cases or the disease they transmit in others, and genetic engineering hold out some hope for the future; these are not sufficiently well advanced to permit wholesale application. 相似文献
20.
This study compared the efficiency of the aromatase inhibitor, anastrazole, with the antioestrogenic receptor blocker, tamoxifen, on normal (NRL) and hyperplastic prostate glands. Forty healthy dogs were classified as NRL (n = 18) or abnormal (ABN) with benign prostate hyperplasia (n = 22). The dogs were randomly assigned to one of the following six groups, treated for 60 days; oral placebo for normal (NRL-PLC; n = 6) and abnormal (ABN-PLC; n = 6), oral anastrazole 0.25–1 mg/day, for normal (NRL-ANZ, n = 6) and abnormal (ABN-ANZ, n = 8) and oral tamoxifen citrate 2.5–10 mg/day for normal (NRL-TMX; n = 6) and abnormal (ABN-TMX; n = 8) dogs. The dogs were evaluated before treatment and then monthly for 4 months. At the end of the treatment, the prostatic volume decreased by 28.5 ± 4.3%, 21.6 ± 6.3% and 0.7 ± 1.0% in the ABN-TMX, ABN-ANZ and ABN-PLC (p < 0.01), respectively. From then on, prostatic volume began to increase without reaching pre-treatment values at the end of the study. In the ABN animals, there were no differences for this parameter between ANZ and TMX treatment (p > 0.1), whereas in the NRL animals ANZ produced a less pronounced decrease (p < 0.05), libido, testicular consistency and scrotal diameter decreased during treatment in the TMX group (p > 0.05). These parameters and sperm volume, count, motility and morphological abnormalities remained unaltered throughout the study in the ANZ and PLC groups (p > 0.05). There were no haematological nor biochemical side effects. Anastrazole might offer a safe and effective alternative for the medical management of dogs with benign prostatic hyperplasia. 相似文献